首页> 外文期刊>Journal of Clinical and Diagnostic Research >Therapeutic Plasma Exchange - An Emerging Treatment Modality in Patients with Neurologic and Non-Neurologic Diseases EC35-EC37
【24h】

Therapeutic Plasma Exchange - An Emerging Treatment Modality in Patients with Neurologic and Non-Neurologic Diseases EC35-EC37

机译:治疗性血浆置换-神经性和非神经性疾病患者的新兴治疗方式EC35-EC37

获取原文
       

摘要

Introduction: Therapeutic Plasma Exchange (TPE) is a procedure in which the patient?s blood is passed through an apheresis machine, where the filtered plasma is removed and discarded with reinfusion of red blood cells along with replacement fluid such as plasma or albumin in to the patient. We present our experience with TPE in treatment of various neurologic and non-neurologic diseases.Aim: To evaluate TPE as primary therapy or as a first-line adjunct to other initial therapies as mentioned by American Society for Apheresis (ASFA).Materials and Methods: A retrospective analysis of TPE procedures was done for a period of nine years, from January 2007 to May 2016 in a tertiary care teaching hospital. A total of 584 TPE procedures were performed in 161 patients between 2 to 75 years of age. Clinical and laboratory investigations like ECG, chest X-ray, cardiorespiratory status and serology were carried out before the TPE procedure.Results: A total of 161 patients were enrolled in the present study. Guillain-Barre Syndrome (GBS) (67.7%, n=109) was the main indication for TPE, followed by Myasthenia Gravis (MG) (13.04%, n=21). Overall incidence of adverse reactions was 9.93%, inadequate vascular access was a common complication encountered in paediatric age group.Conclusion: Our results show that TPE is not only safe and effective treatment alternative to Intravenous Immunoglobulin (IVIG), it also strongly holds evidence in the improvement of neurological disorders compared to non-neurological disorders. There is need of further detail evaluation on large number of cases for proper evidence based practice.
机译:简介:治疗性血浆交换(TPE)是一种将患者的血液通过单采血液分离机的过程,在该过程中,过滤的血浆将被清除并丢弃,并伴随着红细胞以及血浆或白蛋白等置换液的回输。患者。我们介绍了我们在TPE治疗各种神经系统疾病和非神经系统疾病方面的经验。目的:评估TPE是美国疗法协会(ASFA)提到的主要治疗还是其他初始疗法的一线辅助治疗。 :从2007年1月至2016年5月,在三级教学医院对TPE程序进行了为期9年的回顾性分析。在161位2至75岁的患者中共进行了584次TPE手术。在进行TPE手术之前进行了临床和实验室检查,如心电图,胸部X线检查,心肺状况和血清学检查。结果:本研究共纳入161例患者。格林-巴利综合症(GBS)(67.7%,n = 109)是TPE的主要适应症,其次是重症肌无力(MG)(13.04%,n = 21)。不良反应的总发生率为9.93%,血管通路不足是小儿年龄组常见的并发症。结论:我们的研究结果表明,TPE不仅是静脉免疫球蛋白(IVIG)的安全有效替代疗法,而且在以下方面有力的证据与非神经疾病相比,神经疾病的改善。需要对大量案件进行进一步的详细评估,以采取适当的循证做法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号